Oncology Institute Net Worth
Oncology Institute Net Worth Breakdown | TOI |
Oncology Institute Net Worth Analysis
Oncology Institute's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Oncology Institute's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Oncology Institute's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Oncology Institute's net worth analysis. One common approach is to calculate Oncology Institute's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Oncology Institute's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Oncology Institute's net worth. This approach calculates the present value of Oncology Institute's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Oncology Institute's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Oncology Institute's net worth. This involves comparing Oncology Institute's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Oncology Institute's net worth relative to its peers.
Enterprise Value |
|
To determine if Oncology Institute is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oncology Institute's net worth research are outlined below:
| Oncology Institute is way too risky over 90 days horizon | |
| Oncology Institute appears to be risky and price may revert if volatility continues | |
| Oncology Institute has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 393.41 M. Reported Net Loss for the year was (64.66 M) with profit before taxes, overhead, and interest of 59.28 M. | |
| Oncology Institute has about 64.21 M in cash with (26.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Oncology Institute has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: B. Riley Initiates Coverage on Oncology Institute |
Oncology Institute Quarterly Good Will |
|
Oncology Institute uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oncology Institute. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncology Institute's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncology Institute Target Price Consensus
Oncology target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Oncology Institute's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Oncology analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Oncology stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Oncology Institute, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOncology Institute Target Price Projection
Oncology Institute's current and average target prices are 3.64 and 7.00, respectively. The current price of Oncology Institute is the price at which Oncology Institute is currently trading. On the other hand, Oncology Institute's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Oncology Institute Market Quote on 21st of July 2025
Target Price
Analyst Consensus On Oncology Institute Target Price
Know Oncology Institute's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncology Institute is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncology Institute backward and forwards among themselves. Oncology Institute's institutional investor refers to the entity that pools money to purchase Oncology Institute's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2025-03-31 | 247.6 K | Quattro Financial Advisors Llc | 2025-03-31 | 162.7 K | Bank Of New York Mellon Corp | 2025-03-31 | 125.1 K | Goldman Sachs Group Inc | 2025-03-31 | 115.1 K | State Street Corp | 2025-03-31 | 101.3 K | Saba Capital Management, Lp | 2025-03-31 | 94.3 K | Lee Financial Corp | 2025-03-31 | 81.4 K | Hightower Advisors, Llc | 2025-03-31 | 81.4 K | Northern Trust Corp | 2025-03-31 | 77 K | Deerfield Management Co | 2025-03-31 | 3.4 M | Tiff Advisory Services Inc | 2025-03-31 | 3 M |
Follow Oncology Institute's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 321.7 M.Market Cap |
|
Project Oncology Institute's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (18.02) | (17.12) |
When accessing Oncology Institute's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Oncology Institute's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oncology Institute's profitability and make more informed investment decisions.
Evaluate Oncology Institute's management efficiency
Oncology Institute has Return on Asset of (0.1766) % which means that on every $100 spent on assets, it lost $0.1766. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.7762) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.45. The current Return On Capital Employed is estimated to decrease to -0.52. As of now, Oncology Institute's Other Current Assets are increasing as compared to previous years. The Oncology Institute's current Debt To Assets is estimated to increase to 0.75, while Non Currrent Assets Other are projected to decrease to under 377.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.05 | 0.05 | |
| Tangible Book Value Per Share | (0.25) | (0.23) | |
| Enterprise Value Over EBITDA | (1.90) | (1.80) | |
| Price Book Value Ratio | 6.46 | 9.86 | |
| Enterprise Value Multiple | (1.90) | (1.80) | |
| Price Fair Value | 6.46 | 9.86 | |
| Enterprise Value | 96.7 M | 91.8 M |
The management team at Oncology Institute has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.9532 | Revenue | Quarterly Revenue Growth 0.103 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncology Institute insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncology Institute time-series forecasting models is one of many Oncology Institute's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncology Institute's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Oncology Institute Earnings per Share Projection vs Actual
Oncology Institute Corporate Management
| FACHE MD | Chief Officer | Profile | |
| Mark Esq | General Counsel | Profile | |
| Robert Carter | Chief Officer | Profile | |
| Rob Carter | Senior Finance | Profile | |
| Stephen Cella | Senior Finance | Profile | |
| Bradford Hively | CEO Director | Profile | |
| Rakesh MBA | Director Technology | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share | Quarterly Revenue Growth 0.103 | Return On Assets | Return On Equity |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.